Editorial
Who Gets the Most Benefit From the Marshall Plan?
JACC: Clinical Electrophysiology · 2026-09
DOI: 10.1016/j.jacep.2026.08.012 ↗Kurz gefasst
Editorial in der Zeitschrift JACC: Clinical Electrophysiology, 2026-09. Verfasst von Michael Fletcher und 1 weiteren Autor:innen. Beteiligte Einrichtung: Center for Cardiovascular Innovation, Vancouver, Canada; Dilawri Cardiovascular Institute, Vancouver General Hospital, Vancouver, Canada. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
ethanol infusionpersistent atrial fibrillationvein of Marshall
Autor:innen und Institutionen
- Center for Cardiovascular Innovation, Vancouver, Canada; Dilawri Cardiovascular Institute, Vancouver General Hospital, Vancouver, Canada.
- Center for Cardiovascular Innovation, Vancouver, Canada; Dilawri Cardiovascular Institute, Vancouver General Hospital, Vancouver, Canada; Department of Medicine, Montreal Heart Institute, Université de Montréal, Montréa…
Zitieren
APA
Fletcher, M., & Andrade, J. G. (2026). Who Gets the Most Benefit From the Marshall Plan?. JACC: Clinical Electrophysiology. https://doi.org/10.1016/j.jacep.2026.08.012
Vancouver
Fletcher M, Andrade JG. Who Gets the Most Benefit From the Marshall Plan?. JACC: Clinical Electrophysiology. 2026. doi:10.1016/j.jacep.2026.08.012
BibTeX
@article{Fletcher2026,
author = {Fletcher, Michael and Andrade, Jason G},
title = {Who Gets the Most Benefit From the Marshall Plan?},
journal = {JACC: Clinical Electrophysiology},
year = {2026},
doi = {10.1016/j.jacep.2026.08.012}
}
EUVIMED